Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mark Snavely

Physician Assistant, Surgical Melbourne, FL Physician Assistant

NPI 1942678958 CMS profile 10596456

1341 Medical Park Dr, Suite 201, Melbourne, FL 32901

Open in the dashboard

General payments

$10,520

456 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Snavely of Melbourne, FL is reported in the CMS Open Payments database as having received $10,520 across 456 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,765 130
2024 General $2,990 125
2023 General $2,541 103
2022 General $1,556 73
2021 General $669 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Snavely
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Mark Snavely were reported at $2,765. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Mark Snavely Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $669 $111 $36–$285 $132
2022 $1,556 $126 $44–$350 $149
2023 $2,541 $137 $47–$355 $160
2024 $2,990 $146 $49–$384 $164
2025 $2,765 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $2,519 146 payments
  2. AbbVie, Inc. $1,891 83 payments
  3. Regeneron Healthcare Solutions, Inc. $1,119 29 payments
  4. Genzyme Corporation $801 25 payments
  5. E.R. Squibb & Sons, L.L.C. $796 21 payments
  6. Novartis Pharmaceuticals Corporation $649 35 payments
  7. Sun Pharmaceutical Industries Inc. $422 14 payments
  8. Lilly USA, LLC $405 13 payments
  9. Incyte Corporation $283 12 payments
  10. Pfizer Inc. $268 11 payments
  11. Other $1,366 67 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,055 451 payments
  2. Education $465 5 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $2,141 115 payments
  2. DUPIXENT Immunology $984 31 payments
  3. SKYRIZI Immunology $961 38 payments
  4. SOTYKTU $816 22 payments
  5. DUPIXENT Inflammation And Immunology $767 19 payments
  6. SIMPONI ARIA $477 32 payments
  7. STELARA $477 32 payments
  8. REMICADE $477 32 payments
  9. SIMPONI $477 32 payments
  10. SKYRIZI Immunology $431 24 payments
  11. Other $3,899 173 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,380

Median for Physician Assistant: 241

Drug cost

$477,788

Median for Physician Assistant: $4,110

Branded share of claims

8.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 59 $241,460
Otezla Apremilast Brand 20 $109,556
Cosentyx Unoready Pen Secukinumab Brand 12 $83,149
Clobetasol Propionate Generic 322 $14,831
Calcipotriene Generic 11 $5,648
Ketoconazole Generic 192 $4,925
Tretinoin Generic 11 $3,085
Betamethasone Dipropionate Generic 51 $2,280
Fluorouracil Generic 35 $2,123
Minocycline Hcl Generic 46 $1,927

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$238,784

Of which drugs: $59

Medicare patients

1,175

Average age 75

Services billed

5,547

503 women, 672 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Ischemic heart disease 30%
Diabetes 28%
Chronic kidney disease 23%
Atrial fibrillation 20%
Osteoporosis 16%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 37 55 $37

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$1,235 — —
DUPIXENT
$590 59 —
SKYRIZI
$155 — —
RINVOQ
$144 — —
COSENTYX
$119 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

456 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Surgical in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record